Page 44 - MemoriaCIBER2019-ENG

44
CIBER Annual report 2019
Programmes
P1: Myocardial damage and its consequences
Coordinators: Francisco Fernández-Avilés y Juan Delgado Jiménez
In the line of structural and electrophysiological remodelling and scar formation, a collaborative work led by the group of Dr.García-Dorado and Dr.Barrabés stands out in which the role of calpains in modulating isoprotenerol-induced ventricular hypertrophy through modulation of GRK2 is described. In addition, in the context of this programme, CIBERCV participates in the European Project IMI2 aimed at studying cardiomyopathy of the diabetic patient through exhaustive image-based characterisation and biomarkers in a wide case-control cohort of patients with and without type 2 diabetes and with and without heart failure with a normal ejection fraction.
In the research line of genetically caused myocardial damage, the work aimed at studying the genetic variants asso- ciated with cardiomyopathy induced by chemotherapy treatment stands out. In a multicentre, clinical and preclinical multidisciplinary model study led by Dr. García Pavía’s Group, the role of genetic susceptibility in chemotherapy da- mage has been established.
In the line of research in heart failure, it is important to highlight the launch of the FAISCA study “De novo atrial fi- brillation in patients with heart failure: incidence, predictors and relevance”, the result of the first intramural call for Research Projects of the Consortium, led by Dr. González-Juanatey. This is a collaborative initiative generated and funded in the context of CIBERCV in which advanced cardiac imaging techniques will be combined with implantable electrocardiographic monitoring to prospectively study the prevalence and implications of this arrhythmia in a large population of patients with HF.
P2: Arterial Pathology, Myocardial Ischaemia and Structural Heart Pathology
Coordinators: Borja Ibáñez Cabeza y Alberto San Román Calvar
The CIBERCV programme 2 focusses on arterial disease, myocardial ischaemia-reperfusion and structural cardiopathy. The results in 2019 have been successful in attaining scientific achievements and the launch of important collaborative initiatives.
In the line of research into Myocardial Ischaemia and Reperfusion, to be highlighted is the completion of the inclusion of animals in the first blind, multicentre, randomized preclinical trial “CIBERCLAP”. The objective of this initiative is to apply